Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Sep 7;12(9):2544.
doi: 10.3390/cancers12092544.

Latest Development in Multiple Myeloma

Yoichi Imai  1
Affiliations
Editorial

Latest Development in Multiple Myeloma

Yoichi Imai. Cancers (Basel). .

Abstract

Specialists in the field of multiple myeloma (MM) research have written a series of 12 articles (2 original articles, 10 reviews) in the Special Issue "Latest Development in Multiple Myeloma" [...].

Keywords: ASCT; AXL; CAR T-cell therapy; KRAS; MRD; chronic pain; hepatitis B virus; immunotherapy; long-lived plasma cells; miRNAs; multiple myeloma; proteasome inhibitor.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

References

    1. Imai Y., Ohta E., Takeda S., Sunamura S., Ishibashi M., Tamura H., Wang Y.H., Deguchi A., Tanaka J., Maru Y., et al. Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma. JCI Insight. 2016;1:e85061. doi: 10.1172/jci.insight.85061. - DOI - PMC - PubMed
    1. Imai Y., Hirano M., Kobayashi M., Futami M., Tojo A. HDAC inhibitors exert anti-myeloma effects through multiple modes of action. Cancers. 2019;11:475. doi: 10.3390/cancers11040475. - DOI - PMC - PubMed
    1. Weißbach S., Heredia-Guerrero S.C., Barnsteiner S., Großhans L., Bodem J., Starz H., Langer C., Appenzeller S., Knop S., Steinbrunn T., et al. Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in human multiple myeloma cell lines. Cancers. 2020;12:455. doi: 10.3390/cancers12020455. - DOI - PMC - PubMed
    1. Yan S., Vandewalle N., De Beule N., Faict S., Maes K., De Bruyne E., Menu E., Vanderkerken K., De Veirman K. AXL receptor tyrosine kinase as a therapeutic target in hematological malignancies: Focus on multiple myeloma. Cancers. 2019;11:1727. doi: 10.3390/cancers11111727. - DOI - PMC - PubMed
    1. Handa H., Murakami Y., Ishihara R., Kimura-Masuda K., Masuda Y. The role and function of microRNA in the pathogenesis of multiple myeloma. Cancers. 2019;11:1738. doi: 10.3390/cancers11111738. - DOI - PMC - PubMed

Publication types